18.95
+2.99%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Savior Lifetec
Its shares trade on Taipei Exchange under the ticker 4167.TWO. It has been listed since 21 December 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.20bn and net income of TWD 537.4m. At that date it held total assets of TWD 4.18bn and shareholders' equity of TWD 3.78bn.
Savior Lifetec Corp. engages in the development, production, and sale of active pharmaceutical ingredients and finished dosage formulations. The company is headquartered in Jhunan, Miaoli. The company went IPO on 2012-12-21. The Company’s products portfolio mainly consists of Meropenem and Imipenem/Cilastatin, Meropenem as well as Ertapenem, among others, which are used as spectrum antibiotics. In addition, it is involved in the provision of APIs intermediates as well as bio-pharmaceutical technology services. The firm distributes its products to Europe, the Americas, Asia and other markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Dec 2012
- Employees
- 384
- Website
- saviorlifetec.com.tw/en ↗
Leadership
Pay as last reported
- Ms. Rebecca LeeChairman of the Board, since 2018
- Mr. Chih-Fang ChenGeneral Manager
- Mr. Chia-Chu ChouDeputy General Manager, Director, since 2020
- Mr. I-Hsiu ChenDeputy General Manager
- Mr. Ming-Hui ChenDeputy General Manager
- Mr. Yen-Lan LinDeputy General Manager
- Mr. Kuo-Wei LinHead of Finance & Accounting, Corporate Governance Officer
- Mr. Yung-Fa ChenDirector, since 2018
- Mr. Zheng ChenDirector
- Mr. Hsing-Yung ChungDirector
- Mr. Jung-Cheng HsiehDirector
- Mr. Ryh-Yan ChangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Savior Lifetec Corp develops Meropenem and Imipenem/Cilastatin for spectrum antibiotics in the Health Care sector.
- The company distributes products to Europe, the Americas, and Asia through its global market presence.
- Savior Lifetec Corp employs 384 professionals in Pharmaceuticals with a focus on active pharmaceutical ingredients.
Weaknesses
- The company's product portfolio includes only Meropenem, Ertapenem, and Imipenem/Cilastatin without diversification.
- Savior Lifetec Corp has no presence in the Financials or Real Estate sectors.
- The firm's API intermediates and bio-pharmaceutical services lack market expansion details.
Opportunities
- Expanding Meropenem sales in Europe could increase market share in the Health Care industry.
- Growing demand for Ertapenem in the Americas may boost revenue from spectrum antibiotics.
- Savior Lifetec Corp can leverage its API intermediates to enter new markets in Asia.
Threats
- Competition from other Pharmaceuticals companies in the Health Care sector poses a risk.
- Regulatory changes in Europe could affect the distribution of Meropenem.
- Savior Lifetec Corp faces challenges in expanding API intermediates due to market saturation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.